印尼尿路病原体耐药与经验性治疗适宜性:基于人群的监测研究
该研究在印尼两岛于2014年4月至2015年5月开展基于患者的横断面监测,纳入3380例疑似尿路感染患者,获得657株大肠埃希菌和肺炎克雷伯菌的药敏数据。结果显示社区获得性尿路感染中仅磷霉素口服耐药率低于20%,导管相关尿路感染中仅替加环素和磷霉素耐药率低于20%,肺炎克雷伯菌对美罗培南耐药率为21.3%。
要点
- 社区尿路感染中仅磷霉素口服耐药率低于20%。
- 导管相关尿路感染中仅替加环素和磷霉素耐药率低于20%。
- 肺炎克雷伯菌对美罗培南耐药率达21.3%。
核心结论
- 印尼社区和医疗相关尿路感染中大肠埃希菌和肺炎克雷伯菌对常用经验性治疗药物耐药率高。
研究设计与样本
- 2014年4月至2015年5月在印尼两岛的公立和私立医院及诊所开展基于患者的横断面研究。
- 筛查3424例合格患者,3380例(98.7%)纳入最终分析。
- 获得840份阳性培养,其中657株大肠埃希菌和肺炎克雷伯菌有药敏数据。
主要发现
- 社区获得性尿路感染中,磷霉素是唯一口服耐药率低于20%的药物(大肠埃希菌和肺炎克雷伯菌均如此)。
- 导管相关尿路感染中,替加环素和磷霉素是仅有的耐药率低于20%的治疗选择。
- 肺炎克雷伯菌对美罗培南的耐药率为21.3%。
临床怎么用
- 在印尼等耐药高发地区,经验性治疗社区尿路感染可考虑磷霉素。
- 导管相关尿路感染经验性治疗可考虑替加环素或磷霉素。
- 需开展智能耐药监测以指导政策制定和干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Urinary tract infections (UTIs) are a common reason for empirical treatment with broad-spectrum antibiotics worldwide. However, population-based antimicrobial resistance (AMR) prevalence data to inform empirical treatment choice are lacking in many regions, because of limited surveillance capacity. We aimed to assess the prevalence of AMR to commonly used antimicrobial drugs in Escherichia coli and Klebsiella pneumoniae isolated from patients with community- or healthcare-associated UTIs on two islands of Indonesia. METHODS: We performed a cross-sectional patient-based study in public and private hospitals and clinics between April 2014 and May 2015. We screened patients for symptoms of UTIs and through urine dipstick analysis. Urine culture and susceptibility testing were supported by telemicrobiology and interactive virtual laboratory rounds. Surveillance data were entered in forms on mobile phones. RESULTS: Of 3424 eligible patients, 3380 (98.7%) were included in the final analysis, and yielded 840 positive cultures and antimicrobial susceptibility data for 657 E. coli and K. pneumoniae isolates. Fosfomycin was the single oral treatment option with resistance prevalence <20% in both E. coli and K. pneumoniae in community settings. Tigecycline and fosfomycin were the only options for treatment of catheter-associated UTIs with resistance prevalence <20%, whilst the prevalence of resistance to meropenem was 21.3% in K. pneumoniae . CONCLUSIONS: Patient-based surveillance of AMR in E. coli and K. pneumoniae causing UTIs indicates that resistance to the commonly available empirical treatment options is high in Indonesia. Smart AMR surveillance strategies are needed to inform policy makers and to guide interventions.
引用
- Sugianli AK, Ginting F, Kusumawati RL, et al. Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia. J Antimicrob Chemother. 2017. PMID: 28137940. doi:10.1093/jac/dkw578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。